Antidepressant Use Among Adults: United States, 2015-2018
NCHS Data Brief
|October 15, 2020
Summary
In the US, 7.2% of adults experienced major depressive episodes in 2018. Antidepressant use among adults is analyzed by demographics and trends from 2009-2018.
Area of Science:
- Epidemiology
- Public Health
- Pharmacology
Background:
- Major depressive episodes affect a significant portion of the adult population, impacting quality of life and increasing disability.
- Antidepressants are a cornerstone of depression treatment and widely prescribed in the United States.
- Understanding patterns of antidepressant use is crucial for public health initiatives and healthcare planning.
Purpose of the Study:
- To present current prevalence estimates of antidepressant use among U.S. adults (aged 18+).
- To examine antidepressant use across various demographic factors including age, sex, race, Hispanic origin, and education level.
- To describe trends in antidepressant utilization over a ten-year period (2009-2010 to 2017-2018).
Main Methods:
- Analysis of national survey data on antidepressant use in U.S. adults.
- Stratification of prevalence estimates by key demographic variables.
- Examination of temporal trends in antidepressant use over a decade.
Main Results:
- In 2018, an estimated 7.2% of American adults reported a past-year major depressive episode.
- Data brief details prevalence of antidepressant use by age, sex, race, Hispanic origin, and education.
- Trends in antidepressant use from 2009-2010 through 2017-2018 are presented.
Conclusions:
- Antidepressant use is a significant public health indicator in the United States.
- Demographic variations in use highlight potential disparities or differing needs.
- Longitudinal data provides insights into evolving treatment patterns for depression.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
643
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
643
Antidepressant Drugs: Overview
1.1K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.1K
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
1.1K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.1K
Depressive Disorders: MDD and Dysthymia
387
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
387
Diagnostic and Statistical Manual of Mental Disorders (DSM)
623
The Diagnostic and Statistical Manual of Mental Disorders (DSM) serves as the primary classification system for mental health disorders, providing standardized diagnostic criteria for clinicians and researchers. First published by the American Psychiatric Association (APA) in 1952, the DSM has undergone several revisions to reflect evolving psychiatric understanding. The fifth edition, DSM-5, released in 2013, introduced key updates that expanded diagnostic categories and modified diagnostic...
623
Drug Therapy
184
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
184


